retin1

RET-IN-1 is a RET kinase inhibitor with IC50 values of 1 nM for RET (WT), 7 nM for RET (V804M), and 101 nM for RET (G810R).

Secretin (1-6) is the N-terminal part of secretin. It can produce vitro glucose-dependent insulin release induced by secretin.

RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.

RET-IN-14 is a potent inhibitor of RET, capable of acting on RET (WT) (IC50 < 0.51 nM), RET (G810R) (IC50: 9.3 nM), RET (V804M) (IC50: 1.3 nM), BTK (C481S) (IC50: 9.2 nM) and BTK (C481S) (IC50 : 15 nM). RET-IN-14 exhibits potential for tumor studies.

RET-IN-11 is a potent and selective RET inhibitor that acts on RET (IC50: 6.20 nM) and RETV804M (IC50: 18.68 nM). RET-IN-11 induces apoptosis and exhibits anti-proliferative and migratory effects in LC-2/ad cells.

RET-IN-10 is a potent inhibitor of RET, with RET loss-of-function mutations linked to congenital megacolon and gain-of-function mutations associated with various human tumors. RET-IN-10 has demonstrated research potential in cancer diseases.

RET-IN-19 is a potent inhibitor of RET and exhibits anticancer effects on RET-wt (IC50: 6.8 nM) and RET V804M (IC50: 13.51 nM).RET-IN-19 can be used to study non-small cell lung cancer (NSCLC).

RET-IN-17 is a potent inhibitor of RET with potential applications in studies of pain associated with IBS and other gastrointestinal disorders, as well as cancers with constitutive RET kinase activity.

RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).

RET-IN-13, a quinoline-based compound, effectively inhibits the RET kinase, demonstrating IC50 values of 0.5 nM for RET (WT) and 0.9 nM for RET (V804M). It holds promise for research into tumors and intestinal diseases associated with abnormal RET activation.

RET-IN-16 is a potent, selective inhibitor of RET, exhibiting IC50 values of 3.98 nM for RET(WT), 8.42 nM for RET(M918T), 15.05 nM for RET(V804L), 7.86 nM for RET(V804M), 5.43 nM for RET-CCDC6, and 8.86 nM for RET-KIF5B, indicating its high efficacy across different RET mutations. It possesses anticancer properties.

Orexin A (human, rat, mouse) acetate (Hypocretin-1) is an excitatory neuropeptide with analgesic properties. It activates Orexin-1 (OX1R) and Orexin-2 (OX2R) receptors, used for studying neurodegenerative diseases.

rac-Hesperetin-13C-d3 the 13C and deuterated compound of rac-Hesperetin. rac-Hesperetin has a CAS number of 69097-99-0. (Rac)-Hesperetin is the racemate form of of Hesperetin. Hesperetin is a natural flavanone compound, and it exhibits potent inhibitory effects against human UGT activity, making it a broad-spectrum inhibitor. Furthermore, Hesperetin induces apoptosis through the activation of p38 MAPK.